Pharmaceutical combinations of a CDK4/6 inhibitor and a B-RAF inhibitor
US9700557B2 · kind B2 · utility
9Cited by
0References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 25, 2013 |
| Grant date | Jul 11, 2017 |
| Priority date | — |
| Expiry date | Jul 25, 2033 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A pharmaceutical combination comprising (a) CDK4/6 inhibitor (b) a B-Raf inhibitor, and optionally (c) a MEK 1/2 inhibitor; combined preparations and pharmaceutical compositions thereof; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.